A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia☆
Abstract
Objective
To determine the efficacy of combined l-carnitine and l-acetyl-carnitine therapy in infertile males with oligo-astheno-teratozoospermia.
Design
Placebo-controlled double-blind randomized trial.
Setting
University tertiary referral center.
Patient(s)
Sixty infertile patients (aged 20–40 years) with the following baseline sperm selection criteria: concentration, 10 to 40 × 106/mL; forward motility, <15%; total motility, 10% to 40%; and atypical forms, <80%. Fifty-six patients completed the study.
Intervention(s)
Patients were submitted to a combined treatment of l-carnitine (2 g/d) and l-acetyl-carnitine (1 g/d) or of placebo; the study design was 2 months' wash-out, 6 months of therapy or of placebo, and 2 months' follow-up.
Main outcome measure(s)
Variation in the semen parameters that were used for patient selection.
Result(s)
Even though increases were seen in all sperm parameters after combined carnitine treatment, the most significant improvement in sperm motility (both forward and total) was present in patients who had lower initial absolute values of motile sperm (<4 × 106 forward or <5 × 106 total motile spermatozoa per ejaculate).
Conclusion(s)
Combined treatment with l-carnitine and l-acetyl-carnitine in a controlled study of efficacy was effective in increasing sperm motility, especially in groups with lower baseline levels.
Keywords: Male infertility, asthenozoospermia, semen, carnitine, sperm motility
To access this article, please choose from the options below
☆ Supported by the Italian Ministry of University and Research, the University of Rome “La Sapienza,” and the Rome University Hospital of the Faculty of Medicine through grants from Sigma Tau srl (Pomezia–Italy).
PII: S0015-0282(04)00209-2
doi:10.1016/j.fertnstert.2003.10.034
© 2004 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

